Tirzepatide vs Retatrutide: Dual vs Triple Receptor Agonists
Tirzepatide and Retatrutide are both long-acting incretin-receptor agonist peptides. The difference that matters most for researchers is which receptors each one engages.
Research blog: general laboratory-science and literature context. Not medical advice. Sealed Peptides materials are for laboratory research use only, and are not for human or veterinary use.
Receptor targets
- Tirzepatide: dual agonist at the GIP receptor and the GLP-1 receptor.
- Retatrutide: triple agonist at the GIP, GLP-1 and glucagon receptors.
The glucagon-receptor component is the defining difference. In the literature it is studied in relation to energy expenditure and hepatic signaling, pathways a dual agonist does not engage directly.
Structure
Both are single-chain peptides of roughly 39 residues built on a GIP-like backbone, with non-natural amino acids and a fatty-acid side chain attached through a linker. The fatty acid binds serum albumin, which is the main reason both have half-lives measured in days.
Listed molecular weights are about 4813.5 Da for Tirzepatide and about 4731.3 Da for Retatrutide, so a mass spectrum distinguishes them easily.
Laboratory handling
Lipidated peptides of this size can self-associate and adsorb to surfaces. The solubility and aggregation guide covers why diluent, concentration and container material matter, and the net peptide content guide explains why the label mass is not the peptide mass.
A related amylin analog
Cagrilintide is a long-acting amylin analog, a different receptor family again. It is frequently discussed alongside incretin agonists in the literature but is not one.
Terms used in this guide
Related tools and guides
For laboratory research use only. Not for human or veterinary use. This post is general chemistry and literature context and does not describe or endorse any use of Sealed Peptides products.